A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

Trial Profile

A Double Blind, Randomized Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Somatuline Depot (Lanreotide) Injection in the Treatment of Carcinoid Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Malignant carcinoid syndrome; Neuroendocrine tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms ELECT
  • Sponsors Ipsen Biopharmaceuticals; Ipsen Pharma SA
  • Most Recent Events

    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 18 Sep 2017 According to an Ipsen media release, based on the data from this study, the U.S. Food and Drug Administration (FDA) has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment of carcinoid syndrome.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top